

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza

Reyhaneh Zafarnejad¹, Paul M. Griffin¹, Mario Ventresca²

¹Department of Industrial and Manufacturing Engineering, Penn State University, University Park PA 16803, USA

²School of Industrial Engineering, Purdue University, West Lafayette, IN 47906 USA

23 **Abstract**

24 Co-infection of COVID-19 and other respiratory pathogens, including influenza virus family, has
25 been of importance since the beginning of the recent pandemic. As the upcoming flu season arrives
26 in countries with ongoing COVID-19 epidemic, the need for preventive policy actions becomes
27 more critical. We present a joint compartmental SEIRS-SIRS model for the co-circulation of
28 SARS-CoV-2 and influenza and discuss the characteristics of the model, such as the basic
29 reproduction number (R_0) and cases of death and recovery. We implemented the model using 2020
30 to early 2021 data derived from global healthcare organizations and studied the impact of
31 interventions and policy actions such as vaccination, quarantine, and public education. The
32 VENSIM simulation of the model resulted in $R_0 = 7.5$, which is higher than what was reported for
33 the COVID-19 pandemic. Vaccination against COVID-19 dramatically slowed its spread and the
34 co-infection of both diseases significantly, while other types of interventions had a limited impact
35 on the co-dynamics of the diseases given our assumptions. These findings can help provide
36 guidance as to which preventive policies would be most effective at the time of concurrent
37 epidemics, and contributes to the literature as a novel model to simulate and analyze the co-
38 circulation of respiratory pathogens in a compartmental setting that can further be used to study
39 the co-infection of COVID-19 or similar respiratory infections with other diseases.

40 **Keywords**

41 SARS-CoV-2, Influenza, Co-infection, Compartmental Modeling, Vaccination, Quarantining.

42

43

44 **1. Introduction**

45 The recent pandemic pathogen, Severe Acute Respiratory Syndrome Coronavirus-2
46 (SARS-CoV-2), which started in December 2019, has caused a wide range of illness varying from
47 mild symptoms to complicated and severe respiratory response, and in 3% of cases even death¹⁻³.
48 Although at the time of writing this paper available data was limited, recent case reports of
49 concurrent infection of influenza virus in adults and children with SARS-CoV-2 infection have
50 suggested that co-infection may heavily influence morbidity and mortality⁴. Previous literature has
51 shown that co-infections were frequent in patient populations and is of importance for both flu
52 season and deadly variants of SARS-CoV-2⁵⁻⁸. The Centers for Disease Control and Prevention
53 (CDC) has reported that influenza and COVID-19 have overlapping signs and symptoms, and co-
54 infection has been documented in both case reports and case series⁹.

55 The reported impact of existing infection with SARS-CoV-2 and co-infection with other pathogens
56 varies, from negative¹⁰ to not significant¹¹ to positive^{12,13}. For example, Kim et al.¹¹ reports more
57 than 20% of 116 SARS-CoV-2 positive individuals tested over a 20 day period contained one or
58 more additional respiratory pathogens, most often rhinovirus/enterovirus and different types of
59 influenza virus family, although the prevalence of co-infection among COVID-19 positive and
60 negative population was not statistically significant. In another study, Yue et al.¹² showed that the
61 prevalence of co-infection with influenza among a group of COVID-19 positive patients in Wuhan,
62 China was more than 50%, while the prevalence of infection with influenza virus pre-pandemic
63 was less than 1%. In a recent study, Bai et al.¹³ found that influenza A virus (IAV) pre-infection
64 significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell types through an
65 experimental co-infection with IAV and SARS-CoV-2 virus.

66 In terms of preventive policy actions during the recent pandemic, policy makers across the globe
67 designed different strategies to try to control the pandemic¹⁴. In the early stages of the pandemic,
68 while pharmaceutical interventions such as vaccination and medical treatment were not accessible,
69 non-pharmaceutical interventions were widely implemented¹⁵. These interventions, such as mask
70 mandates, social distancing, quarantining, surveillance testing, and contact tracing were
71 substantially effective in slowing down the progression of COVID-19¹⁶⁻¹⁸ and some of them are
72 still in place to date. These non-pharmaceutical interventions were found to reduce the burden of
73 flu as well¹⁹, intuitively due the similarities in respiratory propagation of both viruses and how the
74 parallel spread of diseases were slowed down by general hygiene enforcement and social contact
75 reduction. Vaccination programs for COVID-19, becoming accessible worldwide midway through
76 the pandemic, played a significant role in reducing the spread of COVID-19, and associated
77 hospitalization and mortality²⁰. With the emergence of new variants of COVID-19, vaccination
78 proved to be as impactful although booster doses were required and remain ongoing globally²¹.
79 However, with the rise of new variants, achieving herd immunity still remains out of reach²².
80 Nevertheless, flu shots are promoted by public health officials and are found to be effective in
81 controlling simultaneous outbreak of influenza and COVID-19²³. However, it is unclear how
82 impactful pharmaceutical interventions are in reducing co-infection cases of COVID-19 and
83 influenza.

84 Understanding the co-existence and co-infection of two or more diseases at the same time has been
85 an important and controversial topic in the field of epidemiology. To name a few, in 2016, Naji
86 and Hussein²⁴ proposed a compartmental model describing the dynamics of the spread of two
87 different types of pathogens based on two underlying models of disease spread, an SIS-type disease
88 and an SIRS-type disease. In another study, Tilahun et. al²⁵ studied the co-dynamics of Pneumonia

89 as an airborne disease and Typhoid fever as a vector-based disease using a joint SIRS-SIRS
90 simulation for cost-effective disease control purposes. More recently, Rehman et. al²⁶ developed a
91 mathematical transmission model for the co-infection of dengue fever and COVID-19, and
92 described the co-dynamics of the propagation using qualitative and numerical analysis. However,
93 there is limited literature on modeling the co-existence and co-circulation of SARS-CoV-2 and
94 influenza viruses as two airborne diseases.

95 In this paper, we describe a model of disease progression consisting of two joint compartmental
96 models for COVID-19 and influenza. We further simulate the behavior and transmission dynamics
97 of diseases based on the most recent data including US COVID-19 updates and CDC and WHO
98 guidelines. Moreover, we discuss how our results compare and contrast with observed data and
99 published literature since the COVID-19 pandemic started. Finally, we study the impact of
100 vaccination against COVID-19, and non-pharmaceutical interventions such as education and
101 social distancing on the behavior of COVID-19 – influenza co-circulation. The results of this study
102 could provide useful information for researchers and policy makers as to which policy action could
103 mitigate the negative impacts of concurrent epidemics on mortality rate and total cases of infection.
104 With the possibility of emergence of other respiratory epidemics and pandemics in the future²⁷,
105 mathematical and predictive models of co-infection with multiple diseases could further be used
106 in cost-effectiveness and cost-utility analyses and help develop adaptive and effective policy
107 actions.

108 **2. Materials and Methods**

109 We proposed a SEIRS-SIRS compartmental model to study the co-existence of COVID-19 and
110 influenza and further implemented the Next Generation Method (NGM) to find the basic

111 reproduction rate (R_0). We also performed sensitivity analysis and solved the model for various
112 parameter values in order to understand the effect of interventions and policy actions on the spread
113 of diseases²⁸. We created a simulation model for validation and additional investigations.

114 **2-1. Model Parameters and Relationships**

115 To capture the co-dynamics of COVID-19 and influenza, we developed a joint SEIRS-SIRS
116 compartmental model (Figure 1). This model considers a population (N) that is divided into nine
117 compartments, susceptible (S), COVID-19 exposed (E_c), COVID-19 infectious (I_c), influenza
118 infectious (I_f), COVID-19 and influenza co-infectious (I_{fc}), COVID-19 and influenza co-exposed
119 (E_{fc}), COVID-19 recovered (R_c), influenza recovered (R_f) and COVID-19–influenza co-infectious
120 recovered (R_{fc}). We assumed a closed environment with birth rate and natural death rates both
121 equal to 0, while the number of susceptible population increases by those individuals that lose their
122 temporary immunity²⁹ from the recovered compartment of COVID-19 (R_c), influenza (R_f) and
123 COVID-19–influenza co-infected compartment (R_{fc}) with rates of δ_1 , δ_2 and δ_3 , respectively.

124 *Figure 1 – Schematic flow of the model, parameters and compartments are outlined in section 4.1 and dynamics are*
125 *described in section 4.2. Different colors are utilized to indicated similar components.*

126 Susceptible individuals become infected either with COVID-19 at the rate γ_c and join the COVID-
127 19 exposed compartment (E_c), or with influenza at infection rate γ_f and joining influenza infectious
128 compartment (I_f). Patients that are exposed to COVID-19 will become infectious after the latent
129 period (L_c). Since the latent period for influenza is relatively low (roughly from 0.64³⁰ days to 1.6
130 days³¹), we ignored the latency period for influenza. Similarly, patients already infected with
131 influenza might get infected with COVID-19 with the co-infection rate γ_{fc} and become COVID-
132 19 exposed, and after the latent period become co-infected.

133 The infectious compartment of COVID-19 can receive treatment or recover naturally at the rate β_c
134 and move to COVID-19 recovered compartment (R_c) or die with a death rate of α_c . Similarly, the
135 infected compartment of influenza can receive treatment or recover with a rate of β_f and join the
136 influenza recovered compartment (R_f) or die at a rate of α_f . Moreover, the COVID-19- influenza
137 co-infected compartment transitions from the co-infected compartment to the recovered
138 compartment with a rate of β_{fc} and obtain temporary immunity and therefore join the co-infected
139 recovered compartment (R_{fc}). We assumed that all recovered compartments tend to become
140 susceptible once again, after a specific amount of time (δ_f , δ_c and δ_{fc} for flu recovered, COVID-19
141 recovered and co-infection recovered, respectively).

142 An important assumption we made is considering adjustment parameters, k_1 , k_2 and k_3 as
143 additional coefficients in the model. Since this model is essentially the combination of two disjoint
144 SEIRS and SIRS compartmental models, overlaps are inevitable. Patients might technically belong
145 to more than one compartment in reality, but these models are unable to easily capture this
146 complexity. For the model to produce valid results, we assumed that only a proportion of COVID-
147 19 or influenza infected individuals are at risk for co-infected with the other pathogen, and
148 therefore assigned adjustment probabilities^{25,26}. These additional parameters control the flow
149 between compartments and adjust the daily per capita co-infection rate and recovery rates so that
150 the resulting trends mimic real world observations. Adjustment parameters received values
151 between 0 and 1 with the sum of 1.

152 **5-1. Mathematical Model and adjustments**

$$153 \quad \frac{dS}{dt} = \delta_c R_c + \delta_f R_f + \delta_{fc} R_{fc} - \frac{\gamma_c I_c S}{N} - \frac{\gamma_f I_f S}{N} \quad \text{eq - 1}$$

$$154 \quad \frac{dE_c}{dt} = \frac{\gamma_c I_c S}{N} - \frac{E_c}{L_c} \quad \text{eq - 2}$$

$$155 \quad \frac{dI_c}{dt} = \frac{E_c}{L_c} - \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_2 \beta_c + \alpha_c) I_c \quad \text{eq - 3}$$

$$156 \quad \frac{dI_f}{dt} = \frac{\gamma_f I_f S}{N} - \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_2 \beta_f + \alpha_f) I_f \quad \text{eq - 4}$$

$$157 \quad \frac{dE_{fc}}{dt} = \frac{k_1 \gamma_{fc} I_f I_c}{N} - \frac{E_{fc}}{L_c} \quad \text{eq - 5}$$

$$158 \quad \frac{dI_{fc}}{dt} = \frac{E_{fc}}{L_c} + \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_3 \beta_{fc} + \alpha_{fc}) I_{fc} \quad \text{eq - 6}$$

$$159 \quad \frac{dR_c}{dt} = k_2 \beta_c I_c - \delta_c R_c \quad \text{eq - 7}$$

$$160 \quad \frac{dR_f}{dt} = k_2 \beta_f I_f - \delta_f R_f \quad \text{eq - 8}$$

$$161 \quad \frac{dR_{fc}}{dt} = k_3 \beta_{fc} I_{fc} - \delta_{fc} R_{fc} \quad \text{eq - 9}$$

$$162 \quad N = S + E_c + E_{fc} + I_f + I_c + I_{fc} + R_f + R_c + R_{fc} \quad \text{eq - 10}$$

163 **2-2. Basic Reproduction Number (R_0)**

164 The Basic Reproduction Number (R_0) is used to measure the transmission potential of a disease
 165 and is equal to the average number of secondary infections produced by a typical case of an
 166 infection in a population where everyone is susceptible^{32,33}. The next generation method is used to
 167 calculate the R_0 associated with the model of co-infection of SARS-CoV-2 and influenza virus³⁴.
 168 This system has five infected states: E_c , E_{fc} , I_c , I_f and I_{fc} ; and four uninfected states: S , R_c , R_f and
 169 R_{fc} . Although there are nine states in the model, it is eight-dimensional as the total population size
 170 is constant. At the infection-free steady state, $E_c = E_{fc} = I_c = I_f = I_{fc} = R_c = R_f = R_{fc} = 0$, hence $S =$
 171 N . Therefore, for small $(E_c, E_{fc}, I_c, I_f, I_{fc})$ we have the following non-linear system

$$172 \quad \frac{dE_c}{dt} = \frac{\gamma_c I_c S}{N} - \frac{E_c}{L_c} \quad \text{eq - 11}$$

$$173 \quad \frac{dE_{fc}}{dt} = \frac{k_1 \gamma_{fc} I_f I_c}{N} - \frac{E_{fc}}{L_c} \quad \text{eq - 12}$$

$$174 \quad \frac{dI_c}{dt} = \frac{E_c}{L_c} - \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_2 \beta_c + \alpha_c) I_c \quad \text{eq - 13}$$

$$175 \quad \frac{dI_f}{dt} = \frac{\gamma_f I_f S}{N} - \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_2 \beta_f + \alpha_f) I_f \quad \text{eq - 14}$$

$$176 \quad \frac{dI_{fc}}{dt} = \frac{E_{fc}}{L_c} + \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_3 \beta_{fc} + \alpha_{fc}) I_{fc} \quad \text{eq - 15}$$

177 The transition (F) and transmission (V) matrices are as follows:

178

$$179 \quad F = \begin{pmatrix} 0 & 0 & \gamma_c & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & \gamma_f & 0 \\ 0 & 0 & 0 & 0 & 0 \end{pmatrix} \quad \text{eq - 16}$$

$$180 \quad \text{and } V = \begin{pmatrix} \frac{1}{L_c} & 0 & 0 & 0 & 0 \\ 0 & \frac{1}{L_c} & 0 & 0 & 0 \\ -\frac{1}{L_c} & 0 & k_2 \beta_c + \alpha_c & 0 & 0 \\ 0 & 0 & 0 & k_2 \beta_f + \alpha_f & 0 \\ 0 & -\frac{1}{L_c} & 0 & 0 & k_3 \beta_{fc} + \alpha_{fc} \end{pmatrix} \quad \text{eq - 17}$$

181 The eigenvalues of FV^{-1} are obtained as:

$$182 \quad \lambda_1^* = 0 \quad \text{eq - 18}$$

$$183 \quad \lambda_2^* = 0 \quad \text{eq - 19}$$

$$184 \quad \lambda_3^* = 0 \quad \text{eq - 20}$$

185
$$\lambda_4^* = \frac{\gamma_c}{k_2\beta_c + \alpha_c} \quad \text{eq - 21}$$

186
$$\lambda_5^* = \frac{\gamma_f}{k_2\beta_f + \alpha_f}$$

187 eq - 22

188 The basic reproduction number is computed as the spectral radius of FV^{-1}

189
$$R_0 = \max\{\lambda_1^*, \lambda_2^*, \lambda_3^*, \lambda_4^*, \lambda_5^*\} = \max\{\lambda_4^*, \lambda_5^*\} \quad \text{eq - 23}$$

190 which after simplification is independent from the co-infection rate (γ_{fc}) and co-infection
191 recovery rate (β_{fc}), and depending on the evaluating parameters, the dominant R_0 is merely
192 determined by either COVID-19 or influenza branch. We discuss the implications of R_0 in
193 Section 2-2.

194 **2-3. Simulation**

195 In order to study the co-spread of COVID-19 and influenza based on the proposed model, we
196 developed a system dynamics simulation model in VENSIM software V 8.0.9³⁵. The full model
197 is provided in Appendix 1 and more details will be provided on request. Table 1 summarizes the
198 parameter values and available references implemented in the simulation. We modeled the co-
199 infection of SARS-CoV-2 for the state of Indiana with the population of 6,732,000 according to
200 2019 US census³⁶. The parameter values are derived from 2020 available COVID-19 dashboards
201 and databases. We made necessary assumptions in cases where convenient or proper data was not
202 accessible, the most important of which is the estimation of co-infection rate. As discussed
203 previously in the Introduction, it is still unclear whether infection with COVID-19 or other
204 respiratory pathogens affects the co-infection rate. By roughly estimating the average of values

205 reported in the literature, we assumed that the daily per person co-infection rate is 20% more than
 206 the maximum of infection rate with either COVID-19 or influenza. The rest of the parameters,
 207 references and assumptions are provided in Table 1.

208 Table 1 – Model parameters summary

	Parameter	Value	Description	Reference
Compartments	N	~ 6,732,000	Population (Indiana)	36
	S	195,732	Susceptible population	$N - I_c - I_f - I_{fc}$
	E_c	0	COVID-19 exposed	SEIRS model assumption
	E_{fc}	0	influenza infected and COVID-19 exposed	SEIRS model assumption
	I_c	1	COVID-19 infectious	SEIRS model assumption
	I_f	1	influenza infectious	SIRS model assumption
	I_{fc}	1	COVID-19 an influenza co-infectious	SEIRS model assumption
	R_c	0	Recovered compartment of COVID-19	SEIRS model assumption
	R_f	0	Recovered compartment of influenza	SIRS model assumption
	R_{fc}	0	Recovered compartment of both diseases	SEIRS model assumption
Parameters	δ_c	1/365 (day ⁻¹)	Rate of moving from recovered state to susceptible state – COVID-19	48
	δ_f	1/180 (day ⁻¹)	Rate of moving from recovered state to susceptible state – influenza	48
	δ_{fc}	1/365 (day ⁻¹)	Rate of moving from recovered state to susceptible state – both diseases	Assumption (max of δ_c and δ_f)
	γ_c	0.60756 (person ⁻¹ day ⁻¹)	Transmission rate – COVID-19	49
	γ_f	~ 0.44605 (person ⁻¹ day ⁻¹)	Transmission rate – influenza	⁵⁰ – assumption (At least 20% less contagious than COVID-19)
	γ_{fc}	$\text{Max}\{1.2 * \gamma\} = 0.72$ (person ⁻¹ day ⁻¹)	Transmission rate – co-infection	Assumption (~1.2 times more than healthy people)
	β_c	0.10013 (person ⁻¹ day ⁻¹)	Recovery rate – COVID-19	50
	β_f	0.2 (person ⁻¹ day ⁻¹)	Recovery rate – influenza	51
	β_{fc}	0.1 (person ⁻¹ day ⁻¹)	Recovery rate – Both diseases	Assumption
	L_c	2.5 (days, on average)	Latent period associated with COVID-19	15
	α_c	0.0007 (person ⁻¹ day ⁻¹)	Death rate due to COVID-19	52
	α_f	0.0002 (person ⁻¹ day ⁻¹)	Death rate due to influenza	⁵³ – Assumption
	α_{fc}	$0.0007 * 2.27$ (person ⁻¹ day ⁻¹)	Death rate due to Co-infection	54
ν	0.01 to 0.1 (person ⁻¹ day ⁻¹)	Vaccination rate against COVID-19	44	

	k_1	0.2	Adjustment coefficient	¹¹ , Assumption
	k_2	0.8	Adjustment coefficient	$1 - k_1$
	k_3	1-0.431	Adjustment coefficient	¹¹ , Assumption

209

210 2-4. Interventions

211 The simulation was analyzed for three modified versions of the model to capture the impact of
 212 different intervention settings. The primary model (i.e. the baseline model) assumes COVID-19
 213 and influenza propagation began simultaneously at T=0. The second model includes vaccination
 214 against COVID-19 as a pharmaceutical intervention, and the third model considers the impact of
 215 non-pharmaceutical interventions, such as quarantining, public education and social distancing.
 216 Although the flu occurs mostly as a seasonal disease, for the sake of simplicity we assumed
 217 simultaneous propagation of both COVID-19 and influenza. We simulated the co-circulation of
 218 COVID-19 and influenza for 365 days, for an initial population of $S_0 = 6,732,000$. The initial value
 219 for all other compartments was assumed to be 0 at time T=0, except for the infected compartment
 220 which initially contains 1 patient (local patient zero).

221 In terms of the mathematical structure of the model, the impact of vaccination and
 222 quarantining/public education is described as follows. Vaccination against COVID-19 increases
 223 the rate of exit from the susceptible subgroup:

$$224 \quad \frac{dS}{dt} = \delta_c R_c + \delta_f R_f + \delta_{fc} R_{fc} - \frac{\gamma_c I_c S}{N} - \frac{\gamma_f I_f S}{N} - V.S \quad \text{eq - 24}$$

$$225 \quad \frac{dR_c}{dt} = V.S + k_2 \beta_c I_c - \delta_c R_c \quad \text{eq - 25}$$

226 where V indicates the vaccination rate (person⁻¹ day⁻¹)

227 Quarantining/public education on the other hand affects the rate of infection with COVID-19,
228 influenza as well as the rate of co-infection, through decreasing the contact rate between
229 individuals:

$$230 \quad \gamma_c^{New} = D \cdot \gamma_c \quad \text{eq - 26}$$

$$231 \quad \gamma_f^{New} = D \cdot \gamma_f \quad \text{eq - 27}$$

$$232 \quad \gamma_{fc}^{New} = D \cdot \gamma_{fc} \quad \text{eq - 28}$$

233 where D indicates the decrease in contact rate. The rest of the mathematical model remains
234 unchanged.

235

236 **3. Results**

237 **3-1. Baseline Model Simulation Results**

238 Figure 2 shows an overview of all the compartments present in the model over the course of the
239 simulation, as well as a detailed comparison between compartments. The parameter values were
240 derived from 2020 and early 2021 national and global databases. As demonstrated in Figure 2 and
241 the corresponding subfigures, in the base model with no interventions, the peak for infection of
242 COVID-19 was significantly higher than for influenza and co-infection of both. The three peaks
243 almost occurred at the same period, with a lower peak for the influenza in comparison to COVID-
244 19 and a dramatically lower peak for co-infection in comparison to the other types of infection.
245 Despite similarities between SARS-CoV-2 and influenza virus family, the transmission rate
246 associated with COVID-19 was at least 20 percent (to up to 3 times) higher than influenza. This is
247 why we see a clearly smaller peak of infection associated with influenza.

248 *Figure 2 – An overview of the compartments in the model. The smaller figures illustrate a closer comparison*
249 *between similar compartments, for a 365-day simulation of the Co-infection of COVID-19 and Influenza.*

250 A second and smaller peak in the COVID-19 infected population occurred after around 150 days
251 of the first peak, which is in accordance with previously published data for the US from February
252 20, 2020 to December 21, 2020³⁷. No such behavior was found in association with influenza, which
253 also agrees with the expected behavior of annual influenza epidemy in Indiana population³⁸ prior
254 to any COVID-19 related interventions.

255 On the other hand, the recovered compartment of COVID-19, influenza, and co-infection of both
256 behave differently over time. Three existing recovered compartments (recovered from COVID-
257 19, influenza, or the co-infection of both), experienced a peak at around the same time (COVID-
258 19 is behind due to the incubation period), similar to the infected compartment with the COVID-
259 19 recovered population with a significantly higher peak (due to more cases of infection). We can
260 see that based on this model for a 365-day simulation, after around 9 months almost exclusively
261 COVID-19 remains active and contagious, particularly after the second wave.

262 The susceptible and deceased compartments also showed interesting underlying behaviors over
263 the course of the simulation. Over the first year of pandemic, over 96% of the susceptible
264 population suffered from at least one of the infections which is relatively high. The smaller rise in
265 the susceptible population occurred exactly before the second wave of the COVID-19 pandemic
266 ($T = 229$ days). This indicates that before the second wave, the number of individuals in the
267 susceptible compartment increased due to recruitment of susceptible individuals by recovery.
268 Consequently, the second wave appeared, and an additional number of infected individuals led to
269 another less steep fall in the number of susceptible individuals. The same behavior was observed
270 for the number of deceased populations, more COVID-19 infected individuals in the second wave

271 led to more deaths due to COVID-19, while the number of deaths caused by influenza remained
272 the same (~3481), with a very slight increase for individuals infected with both diseases (~100
273 additional deaths).

274 The simulated death rates and observed trends also mimic recent observations both in the US in
275 general and Indiana³⁷, as the first and second wave in the total COVID-19 deaths during 2020
276 indicates how well this model compares with the published literature.

277 **3-2. Calculation of R_0**

278 Given the information and parameter values provided in Table 1, the basic reproduction number
279 (R_0) can be estimated for the model based on Eq. 23. In this case, we have

$$280 \quad R_0 \approx \max\{0,0,0,2.8, 7.5\} = 7.5$$

281 which in comparison to the median R_0 associated with COVID-19 in the US (5.8 - 95% CI 3.8–
282 8.9)^{39,40} in 2020 and early 2021, as well as R_0 associated with seasonal flu (1.2 – 1.3)⁴¹ indicates
283 higher contagiousness of COVID-19 and influenzas co-circulation.

284 **3-3. Interventions and Policy Actions**

285 To model vaccination against COVID-19, we assumed a transition between the susceptible
286 compartment and the COVID-19 recovered compartment. Individuals in the susceptible group can
287 either get infected by COVID-19 or influenza, or directly go to COVID-19 recovered compartment
288 based on a vaccination rate. Therefore, by running sensitivity analysis on the model with various
289 vaccination rates we estimated the impact of vaccination on co-circulation of infections. On the
290 other hand, quarantine and education of people both were assumed to reduce the number of
291 contacts, mostly among the susceptible population, resulting in a reduction in the rates of infection

292 (γ). In other words, we studied two types of interventions: those affecting the number of contacts
293 per person per day, and those affecting the transition between stages by adding new transition
294 states.

295 *2-3-1. Vaccination against COVID-19*

296 By April 2021, the US has administered more than 3 million vaccine shots per day, or around 0.01
297 shots per person daily across the country³³. To study the impact of vaccination against COVID-
298 19, we defined a varying range for vaccination rate for the state of Indiana, ranging from 0 to 0.005
299 (person per day) and further ran sensitivity analysis on the impact of vaccination rate on the model.
300 Figure 3 demonstrates how sensitive the size of each compartment is to the rate of vaccination. As
301 the rate of vaccination increased, a visible decrease in the number of infected individuals could be
302 identified; daily flu infection and COVID19 – flu co-infection cases decline for at least 85% as the
303 daily per capita vaccination rate increases by 0.0005 person.day⁻¹. This in fact is in accordance
304 with the minute level of reported flu cases in 2020 and early 2021⁴². Similarly, yet more slowly
305 for the COVID-19 daily case, with a 0.001 increase in daily per capita vaccination rate there was
306 a 45% reduction in the total number COVID-19 infected individuals. The second wave of COVID-
307 19 was also mitigated as the vaccination rate increased. The total number of deaths also decreased
308 with the higher prevalence of vaccination. The impact of vaccination was more pronounced on the
309 influenza and co-infection compartments, which can be justified due to lower incubation rate
310 associated with influenza in comparison to COVID-19.

311 An important point to consider here is the fact that, in this setting, higher vaccination rates
312 corresponded to faster transitions between the susceptible compartment and the COVID-19
313 recovered compartment. As mentioned previously, from the modeling perspective, vaccination

314 plays the role of a shortcut from susceptible compartment to recovered compartment. That is why
315 there is a fall in the number of susceptible individuals as the rate of vaccination against COVID-
316 19 increases. This also affects the total number of COVID-19 recovered individuals, which is not
317 entirely due to infection.

318 *Figure 3 – The effect of COVID-19 vaccine on the simulation results – lighter curves indicate smaller rate of*
319 *vaccination.*

320 2-3-2. Quarantine and education

321 In order to study the impact of non-pharmaceutical interventions such as quarantine and
322 education⁴³, we assumed that the contact rate per person can decrease by up to 80% by quarantining
323 non-infected individuals, social distancing and educating the public. This assumption is made to
324 enable the model to capture a wide range of contact rates, without considering the feasibility of
325 providing so in practice. In this case, the simulation structure remains the same as the original
326 simulation except for the values of γ_f , γ_c and γ_{fc} will be reduced by up to 20% of the original
327 values, in increments of 10 percent. As shown in Figure 4, as the contact rate declined from 1
328 (100%) to 0.2 (20%), the total number of deceased individuals dropped dramatically in all the
329 deceased compartments. Similarly, the peak for influenza infection and COVID-19 – influenza
330 infection dampened as the number of contacts decreased. For example, a 50% reduction in the
331 contact rate resulted in more than a 90% reduction in the daily cases of influenza and co-infection
332 and led to a delay of around 75 days in the peak of COVID-19 propagation. However, in the case
333 of individuals with COVID-19 only, the primary effect of the reduction in contact rate was a
334 delayed peak. As the contact rate decreased (from 70% of the maximum effective contact rate to
335 20%), we observed more than 60% reduction in the peak of COVID-19 cases as well.

336 Like what was observed through vaccination, changes in the contact rate induced similar behavior
337 in the model, such as the short-term increase (for a window of about 100 days) in the peak of
338 COVID-19 infection. Similar behavior was found in other compartments of COVID-19 infection
339 branch as well, and in all cases the peak occurred later in time. We can explain this behavior based
340 on both the model structure and assumptions. Here we noticed a steady reduction in influenza
341 infection cases and the number of cases in other influenza related compartments, which indicates
342 the sensitivity of influenza to the contact rate, unlike COVID-19 with a short term increase and
343 further decrease behavior. Since fewer patients moved from the susceptible compartment to the
344 influenza infected compartment (up to 60% less in comparison to COVID-19 cases at the peak),
345 more individuals would remain susceptible and further move to the COVID-19 exposed and
346 infected compartments. This is a weakness of compartment models per se, which prevents
347 individuals from belonging to multiple compartments at the same time. Therefore, we cannot rely
348 on these results to estimate how well education and quarantining can reduce the speed of infection.
349 However, we can claim that reducing the contact rate was associated with delay in when the peak
350 in infection curve occurred.

351 *Figure 4 – The effect of quarantine and education on the simulation results – lighter curves indicate higher decrease*
352 *in the contact rates (1: no decrease in contact rates, 0.2: 20% of the maximum effective contact rate, etc.)*

353 **4. Discussion**

354 In this paper, the co-circulation of SARS-CoV-2 and influenza was studied using a joint SEIRS-
355 SIRS compartmental model, including the impact of various interventions and policy actions. In
356 addition, the basic reproduction number associated with the co-infection of COVID-19 and
357 influenza was computed and found to be heavily influenced by the COVID-19 branch. The basic

358 reproduction number computed based on the model (~ 7.5) was also higher in comparison to R_0
359 associated with COVID-19 or influenza separately, pointing to the importance of understanding
360 and mitigating co-infection.

361 In terms of interventions, the effect of interventions such as vaccination against COVID-19 was
362 found to be significant in controlling the spread of COVID-19 alongside seasonal flu, with more
363 than a 65% reduction in the total number of deceased individuals per year based on a vaccination
364 rate of 3 susceptible individuals out of 1000 per day. Other types of interventions that affect the
365 rate of transmission were not as successful as vaccination in reducing the total number of infected
366 and deceased individuals but did effectively delay the peak in infection. Both interventions resulted
367 in significant decrease in the number of flu cases, which is what was observed in 2020⁴². This
368 implies that preventive interventions against COVID-19, pharmaceutical or non-pharmaceutical,
369 automatically reduced the effect of other circulating respiratory pathogens such as influenza virus
370 family.

371 There are several limitations to our work. For the sake of simplicity, we made several assumptions
372 such as negligible incubation period for influenza, adjustment coefficients, and vaccination only
373 against COVID-19, and parameterized the model with data from the developing, and in some cases
374 contradicting, literature on the ongoing COVID-19 pandemic. Moreover, we limited the simulation
375 to a closed environment with natural rates of birth and death equal to zero, as well as a 365-day
376 simulation period that could lead to missing patterns of disease propagation and multiple waves
377 that might occur over a period longer than a year. The model also only accounts for simultaneous
378 co-infection and not sequential infection for periods shorter than 6 months (the recovery period of
379 influenza) which could lead to biased simulation results. Another limitation to this work is that
380 the influenza virus family was considered to be a seasonal infection, usually occurring in the fall

381 and winter⁴⁴ with a year-round circulation (with an expected peak between December and February
382 in the US). On the other hand, there is lack of agreement in the literature over whether infection
383 with influenza can potentially block infection with COVID-19^{13,45,46}, in this model we only
384 focused on the possibility of higher co-infection rates among patients infected with other
385 pathogens. Further research could increase the accuracy of the current model by relaxing some of
386 those assumptions.

387 Despite these limitations, our model successfully mimicked the observed patterns of COVID-19
388 and flu infections throughout 2020 and early 2021, when the COVID-19 pandemic was still away
389 from an endemic phase. For future work, considering a simple cost-and-effect analysis, this model
390 can assist healthcare policy makers to design and establish more efficient and less costly
391 interventions to control the co-spread of such diseases³⁶. In the times of deadly pandemics such
392 the recent COVID-19 pandemic, making cost-effective decisions regarding control policies can
393 heavily determine how well the economy can tolerate the impacts associated with such chaotic
394 situations.

395 **5. Conclusion**

396 The simulation analysis presented in this work could provide public health officials with modeling
397 tools and information that will help them to issue proper preventive guidelines and policy actions
398 for the upcoming flu season in the southern hemisphere, and particularly in countries with yet
399 ongoing COVID-19 crisis. Moreover, this work contributes to the current literature by introducing
400 a novel epidemic model for simulating the co-dynamics of respiratory infection with two or more
401 infectious pathogens, and has applicability in other settings including co-infection of Sexually
402 Transmitted Diseases (STDS), Human Immunodeficiency Virus (HIV), Bacterial Pneumonia, etc.

403

404 **Author contribution**

405 RZ helped define the problem, helped develop the model, ran the simulations, and helped in the
406 writing of the manuscript. MV helped define the problem, helped interpret the results, and helped
407 in the writing of the manuscript. PG helped interpret the results and helped in the writing of the
408 manuscript.

409 **Supporting information**

410 The VENSIM simulation models used during the current study are available and can be found at
411 [https://github.com/Rey-](https://github.com/Rey-Zafarnejad/A_Joint_Compartmental_Model_for_The_Coinfection_of_SARSCoV2_and_Influenza)
412 [Zafarnejad/A_Joint_Compartmental_Model_for_The_Coinfection_of_SARSCoV2_and_Influen](https://github.com/Rey-Zafarnejad/A_Joint_Compartmental_Model_for_The_Coinfection_of_SARSCoV2_and_Influenza)
413 [za](https://github.com/Rey-Zafarnejad/A_Joint_Compartmental_Model_for_The_Coinfection_of_SARSCoV2_and_Influenza). Further details on the model and simulation can be provided upon request.

414

415 **References**

- 416 1. Asch, D. A. *et al.* Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19
417 During the First 6 Months of the Pandemic. *JAMA Internal Medicine* **181**, 471–478 (2021).
- 418 2. Fontanet, A. *et al.* SARS-CoV-2 variants and ending the COVID-19 pandemic. *The Lancet* **397**, 952–
419 954 (2021).
- 420 3. Mortality Analyses. *Johns Hopkins Coronavirus Resource Center*
421 <https://coronavirus.jhu.edu/data/mortality>.
- 422 4. Calcagno, A. *et al.* Coinfection with other respiratory pathogens in COVID-19 patients. *Clinical*
423 *Microbiology and Infection* **0**, (2020).
- 424 5. Awan, U. A. *et al.* COVID-19 and influenza H1N1: A dangerous combination for Pakistan in the
425 upcoming winter season. *Journal of Medical Virology* **93**, 1875–1877 (2021).
- 426 6. Jing, R. *et al.* Co-infection of COVID-19 and influenza A in a hemodialysis patient: a case report.
427 *BMC Infectious Diseases* **21**, 68 (2021).
- 428 7. Kawai, S. *et al.* How many coinfecting patients with influenza and COVID-19 are there in a single
429 Japanese hospital during the first wave? *Japanese Journal of Infectious Diseases* **advpub**, (2021).
- 430 8. del Rio, C., Omer, S. B. & Malani, P. N. Winter of Omicron—The Evolving COVID-19 Pandemic.
431 *JAMA* **327**, 319–320 (2022).
- 432 9. Nowak, M. D., Sordillo, E. M., Gitman, M. R. & Mondolfi, A. E. P. Coinfection in SARS-CoV-2
433 infected patients: Where are influenza virus and rhinovirus/enterovirus? *Journal of Medical Virology*
434 **92**, 1699–1700 (2020).
- 435 10. Stowe, J. *et al.* *Interactions between SARS-CoV-2 and Influenza and the impact of coinfection on*
436 *disease severity: A test negative design*. <http://medrxiv.org/lookup/doi/10.1101/2020.09.18.20189647>
437 (2020) doi:10.1101/2020.09.18.20189647.
- 438 11. Kim, D., Quinn, J., Pinsky, B., Shah, N. H. & Brown, I. Rates of Co-infection Between SARS-CoV-2
439 and Other Respiratory Pathogens. *JAMA* **323**, 2085 (2020).

- 440 12. Yue, H. *et al.* The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and
441 influenza viruses in patients during COVID-19 outbreak. *Journal of Medical Virology* **92**, 2870–2873
442 (2020).
- 443 13. Bai, L. *et al.* Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. *Cell Research*
444 **31**, 395–403 (2021).
- 445 14. Hsiang, S. *et al.* The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature*
446 **584**, 262–267 (2020).
- 447 15. CDC. Coronavirus Disease 2019 (COVID-19). *Centers for Disease Control and Prevention*
448 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html> (2020).
- 449 16. Soltesz, K. *et al.* The effect of interventions on COVID-19. *Nature* **588**, E26–E28 (2020).
- 450 17. Zafarnejad, R. & Griffin, P. M. Assessing school-based policy actions for COVID-19: An agent-
451 based analysis of incremental infection risk. *Computers in Biology and Medicine* **134**, 104518 (2021).
- 452 18. Ge, Y. *et al.* Impacts of worldwide individual non-pharmaceutical interventions on COVID-19
453 transmission across waves and space. *International Journal of Applied Earth Observation and*
454 *Geoinformation* **106**, 102649 (2022).
- 455 19. Fricke, L. M., Glöckner, S., Dreier, M. & Lange, B. Impact of non-pharmaceutical interventions
456 targeted at COVID-19 pandemic on influenza burden – a systematic review. *Journal of Infection* **82**,
457 1–35 (2021).
- 458 20. Moghadas, S. M. *et al.* The impact of vaccination on COVID-19 outbreaks in the United States.
459 *medRxiv* 2020.11.27.20240051 (2021) doi:10.1101/2020.11.27.20240051.
- 460 21. Buchan, S. A. *et al.* Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic
461 infection and severe outcomes. 2021.12.30.21268565 Preprint at
462 <https://doi.org/10.1101/2021.12.30.21268565> (2022).
- 463 22. Kashte, S., Gulbake, A., El-Amin III, S. F. & Gupta, A. COVID-19 vaccines: rapid development,
464 implications, challenges and future prospects. *Human Cell* **34**, 711–733 (2021).

- 465 23. Paget, J. *et al.* The impact of influenza vaccination on the COVID-19 pandemic? Evidence and
466 lessons for public health policies. *Vaccine* **38**, 6485–6486 (2020).
- 467 24. Naji, R. K. & Hussien, R. M. The Dynamics of Epidemic Model with Two Types of Infectious
468 Diseases and Vertical Transmission. *Journal of Applied Mathematics* **2016**, 1–16 (2016).
- 469 25. Tilahun, G. T., Makinde, O. D. & Malonza, D. Co-dynamics of Pneumonia and Typhoid fever
470 diseases with cost effective optimal control analysis. *Applied Mathematics and Computation* **316**,
471 438–459 (2018).
- 472 26. Rehman, A. ul, Singh, R. & Agarwal, P. Modeling, analysis and prediction of new variants of covid-
473 19 and dengue co-infection on complex network. *Chaos, Solitons & Fractals* **150**, 111008 (2021).
- 474 27. Gray, G. C., Robie, E. R., Studstill, C. J. & Nunn, C. L. Mitigating Future Respiratory Virus
475 Pandemics: New Threats and Approaches to Consider. *Viruses* **13**, 637 (2021).
- 476 28. Dimitrov, N. B. & Meyers, L. A. Mathematical Approaches to Infectious Disease Prediction and
477 Control. in *Risk and Optimization in an Uncertain World* (eds. Hasenbein, J. J., Gray, P. &
478 Greenberg, H. J.) 1–25 (INFORMS, 2010). doi:10.1287/educ.1100.0075.
- 479 29. Shayak, B., Sharma, M. M., Gaur, M. & Mishra, A. K. Impact of reproduction number on the
480 multiwave spreading dynamics of COVID-19 with temporary immunity: A mathematical model.
481 *International Journal of Infectious Diseases* **104**, 649–654 (2021).
- 482 30. Fraser, C. *et al.* Pandemic potential of a strain of influenza A (H1N1): early findings. *Science* **324**,
483 1557–1561 (2009).
- 484 31. Estimating influenza latency and infectious period durations using viral excretion data | Elsevier
485 Enhanced Reader.
486 [https://reader.elsevier.com/reader/sd/pii/S175543651200031X?token=DF4EFC60621620615100C9E](https://reader.elsevier.com/reader/sd/pii/S175543651200031X?token=DF4EFC60621620615100C9E8B5311504ED8DA7405A562CAD9A24D35659688672D0B5FEE716C90EE49D195FE23A439CAF&originRegion=us-east-1&originCreation=20220327211853)
487 [8B5311504ED8DA7405A562CAD9A24D35659688672D0B5FEE716C90EE49D195FE23A439CA](https://reader.elsevier.com/reader/sd/pii/S175543651200031X?token=DF4EFC60621620615100C9E8B5311504ED8DA7405A562CAD9A24D35659688672D0B5FEE716C90EE49D195FE23A439CAF&originRegion=us-east-1&originCreation=20220327211853)
488 [F&originRegion=us-east-1&originCreation=20220327211853](https://reader.elsevier.com/reader/sd/pii/S175543651200031X?token=DF4EFC60621620615100C9E8B5311504ED8DA7405A562CAD9A24D35659688672D0B5FEE716C90EE49D195FE23A439CAF&originRegion=us-east-1&originCreation=20220327211853) doi:10.1016/j.epidem.2012.06.001.
- 489 32. Diekmann, O., Heesterbeek, J. A. P. & Roberts, M. G. The construction of next-generation matrices
490 for compartmental epidemic models. *J. R. Soc. Interface.* **7**, 873–885 (2010).


- 491 33. van den Driessche, P. Reproduction numbers of infectious disease models. *Infect Dis Model* **2**, 288–
492 303 (2017).
- 493 34. Khan, M. A., Khan, Y. & Islam, S. Complex dynamics of an SEIR epidemic model with saturated
494 incidence rate and treatment. *Physica A: Statistical Mechanics and its Applications* **493**, 210–227
495 (2018).
- 496 35. Vensim. <https://vensim.com/>.
- 497 36. U.S. Census Bureau QuickFacts: Indiana. <https://www.census.gov/quickfacts/IN>.
- 498 37. Kennedy, D. M., Zambrano, G. J., Wang, Y. & Neto, O. P. Modeling the effects of intervention
499 strategies on COVID-19 transmission dynamics. *Journal of Clinical Virology* **128**, 104440 (2020).
- 500 38. Maciejewski, R. *et al.* A pandemic influenza modeling and visualization tool. *Journal of Visual*
501 *Languages & Computing* **22**, 268–278 (2011).
- 502 39. Ke, R., Romero-Severson, E., Sanche, S. & Hengartner, N. Estimating the reproductive number R_0 of
503 SARS-CoV-2 in the United States and eight European countries and implications for vaccination.
504 *Journal of Theoretical Biology* **517**, 110621 (2021).
- 505 40. Sanche, S. *et al.* High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome
506 Coronavirus 2 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC.
507 doi:10.3201/eid2607.200282.
- 508 41. Biggerstaff, M., Cauchemez, S., Reed, C., Gambhir, M. & Finelli, L. Estimates of the reproduction
509 number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. *BMC*
510 *Infect Dis* **14**, 480 (2014).
- 511 42. Peek, K. Flu Has Disappeared for More Than a Year. *Scientific American*
512 [https://www.scientificamerican.com/article/flu-has-disappeared-worldwide-during-the-covid-](https://www.scientificamerican.com/article/flu-has-disappeared-worldwide-during-the-covid-pandemic1/)
513 [pandemic1/](https://www.scientificamerican.com/article/flu-has-disappeared-worldwide-during-the-covid-pandemic1/).
- 514 43. Aleta, A. *et al.* Modelling the impact of testing, contact tracing and household quarantine on second
515 waves of COVID-19. *Nat Hum Behav* **4**, 964–971 (2020).
- 516 44. The Flu Season | CDC. <https://www.cdc.gov/flu/about/season/flu-season.htm> (2021).

- 517 45. Pinky, L. & Dobrovolny, H. M. SARS-CoV-2 coinfections: Could influenza and the common cold be
518 beneficial? *Journal of Medical Virology* **92**, 2623–2630 (2020).
- 519 46. Achdout, H. *et al.* Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by
520 influenza immunity but not SARS-CoV-2 immunity. *Nat Commun* **12**, 5819 (2021).
- 521 47. Lee, A. & Morling, J. COVID19: The need for public health in a time of emergency. *Public Health*
522 **182**, 188–189 (2020).
- 523 48. What to Know about a ‘Double-Barreled Flu Season’. *Healthline* [https://www.healthline.com/health-](https://www.healthline.com/health-news/get-the-flu-twice-this-year)
524 [news/get-the-flu-twice-this-year](https://www.healthline.com/health-news/get-the-flu-twice-this-year) (2020).
- 525 49. Mandal, M. *et al.* A model based study on the dynamics of COVID-19: Prediction and control.
526 *Chaos, Solitons & Fractals* **136**, 109889 (2020).
- 527 50. Doctor explains how one coronavirus patient can infect 59,000 others. *The Independent*
528 [https://www.independent.co.uk/news/health/coronavirus-infections-symptoms-flu-doctor-dispatches-](https://www.independent.co.uk/news/health/coronavirus-infections-symptoms-flu-doctor-dispatches-a9419146.html)
529 [a9419146.html](https://www.independent.co.uk/news/health/coronavirus-infections-symptoms-flu-doctor-dispatches-a9419146.html) (2020).
- 530 51. Using the SIR Model to Model the Spread of Influenza. *UKDiss.com*
531 <https://ukdiss.com/examples/sir-model-spread-of-influenza.php>.
- 532 52. Mortality Analyses - Johns Hopkins Coronavirus Resource Center.
533 <https://coronavirus.jhu.edu/data/mortality>.
- 534 53. CDC. Burden of Influenza. *Centers for Disease Control and Prevention*
535 <https://www.cdc.gov/flu/about/burden/index.html> (2020).
- 536 54. Iacobucci, G. Covid-19: Risk of death more than doubled in people who also had flu, English data
537 show. *BMJ* **370**, (2020).

538

1 **Figures**

2 Figure 1 illustrates the model described in Section 4.1. The corresponding dynamics are provided
3 in Equations 1 – 10.



4

5 *Figure 1 – Schematic flow of the model, parameters and compartments are outlined in section 4.1 and dynamics are*
6 *described in section 4.2. Different colors are utilized to indicated similar components.*

7

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.26.22279281>; this version posted August 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





Figure 2 – An overview of the compartments in the model. The smaller figures illustrate a closer comparison


between similar compartments, for a 365-day simulation of the Co-infection of COVID-19 and Influenza.

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.26.22279281>; this version posted August 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



13 *Figure 3 – The effect of COVID-19 vaccine on the simulation results – lighter curves indicate smaller rate of*
 14 *vaccination.*

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.26.22279281>; this version posted August 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



16 Figure 4 – The effect of quarantine and education on the simulation results – lighter curves indicate higher decrease
 17 in the contact rates (1: no decrease in contact rates, 0.2: 20% of the maximum effective contact rate, etc.)